TY - JOUR
T1 - Chronic myelogenous leukemia
T2 - A review and update of therapeutic strategies
AU - Garcia-Manero, Guillermo
AU - Faderl, Stefan
AU - O'Brien, Susan
AU - Cortes, Jorge
AU - Talpaz, Moshe
AU - Kantarjian, Hagop M.
PY - 2003/8/1
Y1 - 2003/8/1
N2 - The prognosis of patients with chronic myelogenous leukemia (CML) has significantly improved over the last 20 years. Whereas the median survival durations were 4-5 years in the era of hydroxyurea therapy, the introduction of interferon-a, both alone and in combination with cytosine arabinoside, has nearly doubled these numbers. However, the development of imatinib, a BCR-ABL selective tyrosine kinase inhibitor, represents one of the biggest leaps forward in the treatment of CML and will probably have a significant impact on the course and potential one of CML. Here, we review the biology of CML, its clinical features, and therapeutic options in this disease.
AB - The prognosis of patients with chronic myelogenous leukemia (CML) has significantly improved over the last 20 years. Whereas the median survival durations were 4-5 years in the era of hydroxyurea therapy, the introduction of interferon-a, both alone and in combination with cytosine arabinoside, has nearly doubled these numbers. However, the development of imatinib, a BCR-ABL selective tyrosine kinase inhibitor, represents one of the biggest leaps forward in the treatment of CML and will probably have a significant impact on the course and potential one of CML. Here, we review the biology of CML, its clinical features, and therapeutic options in this disease.
UR - http://www.scopus.com/inward/record.url?scp=0038299199&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038299199&partnerID=8YFLogxK
U2 - 10.1002/cncr.11520
DO - 10.1002/cncr.11520
M3 - Review article
C2 - 12879460
AN - SCOPUS:0038299199
SN - 0008-543X
VL - 98
SP - 437
EP - 457
JO - Cancer
JF - Cancer
IS - 3
ER -
